Signadori Bio
About Signadori Bio
Signadori Bio is a Oncology startup based in Paris, France that has raised $11M in venture capital across 1 funding round since 2025. The company reached Seed stage in May 2026 with a $11M round led by Taiho Ventures. Signadori Bio's investor base includes 3 institutional funds, with Taiho Ventures leading the most recent equity round.
Signadori Bio is a preclinical-stage biopharmaceutical company developing a next-generation, off-the-shelf in vivo monocyte immunotherapy platform designed to treat solid tumours by engineering innate immune cells directly within the patient.
Signadori Bio Funding Rounds Timeline
1 rounds · $11M raised · since 2025
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Seed | May 2026 | $11M | — | Taiho Ventures | Sofinnova Partners, Invivo Partners |
Investors in Signadori Bio
3 institutional investors across 1 rounds
Lead investors
Co-investors
Recent news about Signadori Bio
- startup_fundraisingSignadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform
Questions about Signadori Bio
How much has Signadori Bio raised?
Signadori Bio has raised $11M across 1 funding round since 2025.
Who are the investors of Signadori Bio?
Signadori Bio's investors include Taiho Ventures, Sofinnova Partners, Invivo Partners.
When was Signadori Bio's last funding round?
Signadori Bio's most recent round was a $11M Seed in May 2026, led by Taiho Ventures.
Where is Signadori Bio headquartered?
Signadori Bio is headquartered in Paris, France, and was founded in 2025.